MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h [i] j k l m n o p q r s t u v w x y z
  • Identification and Characterization of Selective and High Affinity Small Molecules as Positron Emission Tomography (PET) Imaging Tracers for Pathological Alpha-Synuclein

    E. Tsika, E. Vokali, J. Molette, M. Ravache, P. Rodriguez, V. Darmency, K. Piorkowska, S. Poli, H. Kroth, F. Capotosti, D. Lowe, J. Stoehr, M. Kosco-Vilbois, A. Pfeifer, A. Muhs (Lausanne, Switzerland)

  • Identification of aberrant circulating miRNAs in Parkinson’s disease plasma samples

    L. Chen, J. Yang (Tianjin, China)

  • Identification of candidates for device-assisted therapy in Parkinson’s disease using Artificial Neural Networks

    C. Valderrama Martín, L. Triguero Cueva, MJ. Pérez Navarro, CJ. Madrid Navarro, R. Calle Calle, I. Rego García, A. Mínguez Castellanos, IM. Galván León, F. Escamilla Sevilla (Granada, Spain)

  • Identification of genetic alterations and SNCA mutation in Parkinson’s disease patients of Coimbatore Population, India

    D. Venkatesan, B. Vellingiri (Coimbatore, India)

  • Identification of modifier genes related to G proteins pathways on the motor capacity of a Drosophila melanogaster model of Friedreich’s ataxia

    EG. Zucchet, J. Gonzalez, P. Calap, P. Gonzalez Cabo, MD. Moltó Ruiz (Valencia, Spain)

  • Identification of potential new genes involved in autosomal recessive forms of Parkinson’s disease

    C. Tesson, A. Honoré, V. Drouet, H. Bertrand, S. Lesage, A. Brice (Paris, France)

  • Identification of protein biomarker/s in CSF of Parkinson’s disease (PD) with cognitive impairment

    A. Naskar, A. Stezin, D. Gadara, S. Ahuja, V. Menon, N. Kamble, J. Saini, S. Hegde, U. Tatu, P. Pal, P. Alladi (Bangalore, India)

  • Identifying altered resting state network connectivity in Parkinson’s disease with mild cognitive impairment

    J. Yang, K. Mcmahon, D. Copland, G. Byrne, J. O'Sullivan, N. Dissanayaka (Herston, Australia)

  • Identifying delirium in people with Parkinson’s disease: the Determine-PD pilot study

    R. Lawson, S. Richardson, A. Yarnall, D. Burn, L. Allan (Newcastle Upon Tyne, United Kingdom)

  • Identifying genetic Parkinson’s disease patients worldwide: Exploiting novel ways of team science

    E-J. Vollstedt, M. Kasten, C. Klein (Lübeck, Germany)

  • Identifying healthy Parkin mutation carriers based on sensor-based posturography and gait analysis

    J. Prasuhn, M. Borsche, A. Hicks, M. Gögele, C. Egger, C. Kritzinger, L. Langlott, M. Kasten, C. Klein, P. Pramstaller, N. Brüggemann (Lübeck, Germany)

  • Identifying In-Clinic Wearable Sensor Features that Predict Parkinson’s Disease Severity

    A. Dowling, A. Mirelman, J. Hausdorff, M. Sela, O. Assais, N. Giladi, J. Cedarbaum (Cambridge, MA, USA)

  • Identifying Incident Cases of Neurodegenerative Parkinsonism in a Large Observational At-Risk Cohort: the PPMI study

    L. Chahine, K. Kieburtz, M. Brumm, C. Caspell-Garcia, C. Coffey, A. Siderowf, D. Weintraub, C. Tanner, T. Foroud, D. Galasko, B. Mollenhauer, T. Simuni, K. Marek (Pittsburgh, PA, USA)

  • Identifying perceptual, motor and cognitive components contributing to the slowness of information processing in Parkinson’s disease and the implication in the quality of life

    A. Arroyo, J. Andreo, J. Periañez, G. Lubrini, M. Rios, JP. Romero (Pozuelo de Alarcon, Spain)

  • Identifying subtypes of Mild Cognitive Impairment in Parkinson’s disease using cluster analysis

    D. Pourzinal, JH. Yang, G. Byrne, J. O'Sullivan, L. Mitchell, K. Mcmahon, D. Copland, N. Dissanayaka (St Lucia, Australia)

  • Identifying the association of depression and distress in Pakistani patients diagnosed with Parkinsonism syndrome

    A. Fatima (Lahore, Pakistan)

  • Imaging biomarker for progression of motor symptoms in advanced Parkinson’s disease

    K. Furukawa, N. Sawamoto, A. Shima, D. Kambe, A. Nishida, I. Wada, H. Sakamaki, K. Yoshimura, Y. Fushimi, T. Okada, K. Togashi, R. Takahashi (Kyoto, Japan)

  • Imaging Brain Insulin Resistance in Parkinson’s Disease using [¹⁸F]FDG-PET

    E. Hogg, P. Linesch, T. Wu, E. Tan, Z. Fan, W. Gao, A. Waxman, M. Tagliati (Los Angeles, CA, USA)

  • Imaging correlates of impaired self-awareness of cognitive deficits in Parkinson’s disease

    F. Maier, A. Greuel, M. Hoock, M. Tahmasian, F. Jessen, I. Csoti, L. Timmermann, C. Eggers (Cologne, Germany)

  • Imaging Parkinson’s disease pathology: A comparison between neuromelanin-sensitive MRI, susceptibility weighted imaging and [11C]PE2I DAT PET

    A. Chandra, G. Pagano, T. Yousaf, H. Wilson, M. Politis (London, United Kingdom)

  • Immediate effect of the virtual and augmented reality and neurofunctional physiotherapy on postural control and cognition in patients with Parkinson’s disease: a randomized clinical trial

    S. Smaili, H. Araújo, R. de Souza, T. da Silva, T. Nascimento, M. Terra (Londrina, Brazil)

  • Immediate Effects of Non-Motorized Treadmill Training for One Session on Gait and Fall Risk In Parkinson’s Disease

    A. Boddy, K. Mitchell, W. Brewer, J. Ellison (St. Augustine, FL, USA)

  • Impact of a high-fat diet on the behavior of A53T alpha-Synuclein Parkinson’s disease mice

    M. Temmel, V. Niederkofler, R. Rabl, H. Roemer, B. Hutter-Paier (Grambach, Austria)

  • Impact of caring for patients with Huntington’s disease on work status

    K. Raimundo, R. Tan, T. To, J. de Courcy, U. Ondhia, H. Rickards, M. Nance (San Francisco, CA, USA)

  • Impact of cathine and carthinone use among Parkinson’s disease Patients

    S. Zewde (Addis Ababa, Ethiopia)

  • Impact of cathine and cathinone use among Parkinson’s disease Patients

    S. Zewde (Addis Ababa, Ethiopia)

  • Impact of Cognitive Profile on Impulse Control Disorders Presence and Severity in Parkinson’s Disease

    A. Martini, L. Weis, E. Fiorenzato, R. Schifano, V. Cianci, A. Antonini, R. Biundo (Newcastle-­under­-Lyme, United Kingdom)

  • Impact of fixed or flexible abobotulinumtoxinA injection intervals on patient outcomes: Analyses from a 3-year observational study following patients with cervical dystonia

    C. Colosimo, T. Chung, D. Charles, V. Misra, S. Om, P. Maisonobe (Terni, Italy)

  • Impact of ND0612 on patient reported outcomes: A blinded rater study of 2 dosing regimens

    F. Stocchi, W. Poewe, S. Oren, R. Case, K. Kieburtz, C. Olanow (Rome, Italy)

  • Impact of Nordik Walking training in patients with Progressive Supranuclear Palsy

    R. Kandel, B. Bhattarai (Lalitpur, Nepal)

  • Impact of OFF periods on aspects of employment for people with Parkinson’s disease

    I. Iresha Abeynayake, L. Marinucci, M. Klingler, C. Kenney (Aardsley, NY, USA)

  • Impact of Offering Genetic Testing and Counseling to People with Parkinson’s Disease in a Clinical Setting

    A. Naito, J. Beck, C. Casaceli, A. Hall, K. Marder, M. Nance, M. Schwarzschild, T. Simuni, R. Alcalay (Miami, FL, USA)

  • Impact of oral COMT-inhibitors on gut microbiota and biologically active microbial metabolites in patients with Parkinson’s Disease

    D. Grün, V. Zimmer, J. Kauffmann, M. Unger, J. Spiegel, KU. Dillmann, A. Schwiertz, K. Faßbender, M. Fousse (Homburg, Germany)

  • Impact of overweight and obesity on functional and clinical outcomes of early Parkinson’s disease

    R. Kim, JS. Jun (Seoul, Republic of Korea)

  • IMPACT OF PAIN ON STROKE AND HYPERTENSION AS COMORBIDITIES IN PARKINSON’S DISEASE

    V. Wijaya, R. Pinzon, A. Al Jody (Yogyakarta, Indonesia)

  • Impact of pallidal deep brain stimulation on activities of daily living in patients with craniocervical dystonia – a multi-center survey

    J. Huebl, T. Andermann, C. Blahak, J. Krauss, M. Südmeyer, J. Volkmann, K. Bötzel, A. Wolters, A. Kühn (Berlin, Germany)

  • Impact of quantitative assessment of parkinsonian symptoms using wearable technology on treatment decisions

    C. Thomas, B. Mohamed, M. Silverdale, C. Kobylecki, L. Osborne, R. Saha, P. Bain, D. Heisters, C. Carroll (Cardiff, United Kingdom)

  • Impact of repeated oral administration of Opicapone on the plasma pharmacokinetics of levodopa

    M. Nomoto, A. Takeda, K. Iwai, A. Nishimura, N. Hattori (Ehime, Japan)

  • Impact of Sub-Thalamic Nucleus Deep Brain Stimulation on Cognition and Behavior in Parkinson Patients

    F. Mameli, F. Ruggiero, M. Reitano, E. Gianoli, D. Tedino, L. Borellini, F. Cogiamanian, S. Barbieri, A. Priori, R. Ferrucci (Milan, Italy)

  • Impact of subthalamic deep brain stimulation on sensorimotor and motor cortical oscillatory activity in free-moving hemiparkinsonian rats

    A. Abdulbaki, T. Doll, J. Krauss, M. Alam, K. Schwabe (Hannover, Germany)

  • Impact of the Home Environment on Falls Risk: A Cross-Sectional Study of Patients with Parkinson’s Disease

    Y. Thongchuam, S. Phumphid, O. Phokaewvarangkul, R. Bhidayasiri (Bangkok, Thailand)

  • Impaired cerebral vasoreactivity in patients with Parkinson’s disease: clinical and imaging correlates

    I. Estrada-Bellmann, D. Cantú-García, S. Castillo-Torres, A. Mendoza-García, H. Sánchez-Terán, D. Díaz-Pérez, D. Roque-Martínez, S. Saldívar-Dávila, H. Martínez, T. Moreno-Andrade, B. Chávez-Luévanos, F. Góngora-Rivera (Monterrey, NL, Mexico)

  • Impaired colour discrimination is associated with hallucinations in Dementia with Lewy Bodies

    E. Matar, K. Ehgoetz Martens, J. Phillips, G. Halliday, S. Lewis (Sydney, Australia)

  • Impaired fonction of mirror neurons and the role of levodopa in PD patients

    T. Danaila, P. Jaulent, C. Laurencin, J. Xie, H. Klinger, P. Krolak-Salmon, S. Thobois (Lyon, France)

  • Impaired intracortical inhibition predicts response to medication in Parkinson’s disease patients

    SR. Filipović, A. Kačar, S. Milanović, M. Ljubisavljević, VS. Kostić (Beograd, Serbia)

  • Impaired LTP-like plasticity in Parkinson’s Disease can be restored by γ-transcranial alternating current stimulation

    A. Guerra, A. Suppa, F. Asci, V. D'Onofrio, V. Sveva, M. Bologna, A. Berardelli (Rome, Italy)

  • Impaired lysosomal catabolism of alpha-synuclein in parkinsonian LRRK2(R1441G) mutant mouse embryonic fibroblasts

    WL. Ho, CT. Leung, HF. Liu, LF. Li, DB. Ramsden, SL. Ho (Hong Kong, Hong Kong)

  • Impairment of Neurological Ontogenesis in Children with Austism Spectrum Disorders

    V. Kozyavkin, T. Voloshyn (Truskavets, Ukraine)

  • Implementation of a Peer-to-Peer Mentoring Intervention for Center of Excellence Coordinators

    C. Hunter, K. Arney, J. Fleisher, P. Palmentera, J. Shurer, F. Cubillos (Houston, TX, USA)

  • Improvement of Essential Tremor after Cortical Cerebral Infarction

    D. Riley (Warrensville Heights, OH, USA)

  • Improvement of lower extremity Holmes tremor with intrathecal baclofen: First Report

    S. Saad, C. Kilbane, H. Abboud (Cleveland, OH, USA)

  • Improvements in gait deficits with peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson’s disease during deep brain stimulation surgery: 2-year follow-up study

    G. Gera, K. Rickard, C. Crumpton, A. Borgsmiller, Z. Guduru, C. Horne, G. Qunitero (Lexington, KY, USA)

  • Improving neuroprotective effects of resveratrol by brain targeting through chitosan glutamate nanoparticles in MPTP induced parkinsonism

    M-R. Rahman, V-K. Kumar (Allahabad, India)

  • Improving outcomes in hospitalized Parkinson’s patients

    S. Aslam, E. Simpson, M. Baugh, H. Shill (Phoenix, AZ, USA)

  • Impulse control and pain : a link in Parkinson’s disease.

    G. Albani, L. Pradotto, G. Veneziano, P. Cipresso, E. Pedroli, F. Scarpina, A. Mauro, M. Semonella, A. Cistaro (Piancavallo-Verbania, Italy)

  • Impulse control and repetitive behavior disorders are more common in PD patients with levodopa-induced dyskinesias

    F. Paolini Paoletti, N. Tambasco, G. Cappelletti, P. Eusebi, S. Simoni, P. Nigro, E. Brahimi, M. Filidei, P. Calabresi (Perugia, Italy)

  • Impulse Control Disorder (ICD) in the Patient with Parkinson’s Disease (PD)

    M. Kulsum, S. Choudhury, A. Ghosh, P. Ghosh (Kolkata, India)

  • Impulse control disorders and (romantic) jealousy in Parkinson’s disease: a patients’ vs. partners’ perspective

    E. Pipan, S. Delalić, A. Herzog, M. Trošt, Z. Pirtošek, D. Flisar, N. Kovacs, D. Georgiev (Ljubljana, Slovenia)

  • Impulse Control Disorders in a Brazilian population with Parkinson´s disease -an observational study

    B. Veiga, V. Borges, H. Ferraz, C. Aquino, C. Giacominelli, SM. Silva, S. Lestingi (São Paulo, Brazil)

  • In the shadow of Parkinson disease: what to tell patients with REM sleep behavior disorder?

    D. Barone, A. Lee, N. Hellmers, S. Lakhani, H. Sarva, C. Henchcliffe (New York, NY, USA)

  • In vivo and In vitro study of 17β estradiol against amyloid beta neurotoxicity in synaptosomes of aging female rats : A therapeutic potential drug for Alzheimer’s disease

    P. Kumar, N. Baquer (New Delhi, India)

  • In vivo increased striatal iron deposition in Parkinson’s Disease Dementia and Dementia with Lewy Body

    S. Rota, T. Yousaf, H. Wilson, G. Dervenoulas, G. Pagano, D. Aarsland, M. Politis (London, United Kingdom)

  • Incidence of drooling in Parkinson’s Disease and Impact on Quality of Life

    B. Gibbons, B. Mohamed, C. Thomas (Cardiff, United Kingdom)

  • Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline body mass index: post-hoc analysis from double-blind combined BIPARK-I and II data.

    F. Ikedo, J. Ferreira, A. Lees, E. Tolosa, W. Poewe, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

  • Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline disease severity: post-hoc analysis from double-blind combined BIPARK-I and II data

    R. Costa, A. Lees, J. Ferreira, O. Rascol, F. Stocchi, H. Gama, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

  • Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline dopamine agonist use: post-hoc analysis from double-blind combined BIPARK-I and II data

    F. Ikedo, A. Lees, J. Ferreira, O. Rascol, F. Stocchi, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

  • Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline MAO-B inhibitors use: post-hoc analysis from double-blind combined BIPARK-I and II data

    R. Costa, J. Ferreira, A. Lees, E. Tolosa, W. Poewe, H. Gama, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

  • Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to gender: post-hoc analysis from double-blind combined BIPARK-I and II data

    F. Ikedo, J. Ferreira, A. Lees, E. Tolosa, W. Poewe, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

  • Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to race: post-hoc analysis from double-blind combined BIPARK-I and II data.

    R. Costa, A. Lees, J. Ferreira, O. Rascol, F. Stocchi, H. Gama, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

  • Incidental iron deposition in basal ganglia: does the pattern matter? Fifteen years’ experience in a tertiary care center.

    á. Beltrán Corbellini, P. Pérez Torre, A. Alonso Cánovas, F. Rodríguez Jorge, JL. Chico García, P. Parra Díaz, E. Natera Villalba, A. Gómez López, S. Fanjul Arbos, JL. López Sendón, JC. Martínez Castrillo, I. Parées Moreno (Madrid, Spain)

  • IncobotulinumtoxinA is effective, long lasting and well tolerated treatment of hemifacial spasm

    S. Ochudlo, A. Krzak-Kubica, J. Gawryluk (Katowice, Poland)

  • Incongruity of Functional Tremor Predicts Better Response to Transcranial Magnetic Stimulation Treatment

    N. Prezelj, K. Vogelnik, Z. Pirtošek, M. Kojović (Ljubljana, Slovenia)

  • Increased Brain-Chin/Leg EEG Synchronicity in Sleep in Parkinson’s Disease

    O. Vaou, A. Depold Hohler, J. Wang, X. Zhang, F. Lombardi, A. Quaicoe, R. Endalapur, J. Holsapple, P. Ivanov (Boston, MA, USA)

  • Increased fractional anisotropy in precuneus in Parkinson’s disease without mild cognitive impairment – a diffusion tensor imaging study

    A. Nagano-Saito, J. Houde, C. Bedetti, M. Côté, O. Monchi (Montreal, QC, Canada)

  • Increased hub function in posterior medial cortex in Parkinson’s disease without mild cognitive impairement – A resting state fMRI study –

    A. Nagano-Saito, P. Bellec, S. Jobert, B. Mejia-Constain, C. Degroot, A. Lafontaine, A. Hanganu, J. Lissemore, K. Smart, C. Benkelfat, O. Monchi (Montreal, QC, Canada)

  • Increased level of a lysosomal phospholipid, BMP, in urine of LRRK2 G2019S mutation carriers with or without Parkinson’s disease: implications for therapeutic development

    R. Alcalay, F. Hsieh, S. Padmanabhan, M. Baptista, C. Kehow, S. Narayan, A. Boehme, K. Merchant (Cambridge, MA, USA)

  • Increased lysosphingolipids levels in blood of patients with multiple system atrophy

    K. Senkevich, G. Baydakova, A. Emelyanov, M. Nikolaev, A. Kopytova, I. Miliukhina, E. Gracheva, A. Kudrevatykh, I. Krasakov, L. Khublarova, I. Fursova, Y. Irishina, N. Zalutskaya, Y. Beltseva, E. Zakharova, S. Pchelina (Saint-Petersburg, Russian Federation)

  • Increased vesicular monoamine transporter alleviate MPTP-induced impairment of neurogenesis

    K. Ma, G. Zhang, C. Han, X. Guo, Y. Xia, F. Wan, L. Kou, S. Yin, L. Liu, N. Xiong, J. Huang, T. Wang (Wuhan, China)

  • Increasing chances of detecting a neuroprotective signal in PhI/II PD clinical trials?

    S. Palfi, C. Denot, A. Bousseau, JC. Corvol (Paris, France)

  • Inertial Sensor-Based Tremor and Bradykinesia Quantification and Potential for Early Disease Identification in Fragile X-associated Tremor/Ataxia Syndrome (FXTAS)

    D. Bang, D. Hall, J. Joyce, E. Robertson, G. Pal, J. O'Keefe (Chicago, IL, USA)

  • Inflammatory Conditions in Parkinson’s Disease

    B. Krishnamachari, S. Shermon, M. Goldfinger, A. Leder, B. Harper, J. Donoghue (Old Westbury, NY, USA)

  • Inflammatory cytokines in Saudi Parkinson cohort

    N. Alsomali, E. Al-Ofi, M. Obaid, A. Alrafiah (Riyadh, Saudi Arabia)

  • Influence of baseline OFF-time in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II

    A. Santos, J. Ferreira, A. Lees, H. Reichmann, W. Poewe, F. Ikedo, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

  • Influence of cognitive abilities on prominence production in mild dysarthric patients with Parkinson’s disease

    T. Thies, D. Mücke, A. Lowit, J. Steffen, E. Kalbe, M. Barbe (Cologne, Germany)

  • Influence of Cognitive Deficits and Tremor Severity of the Development of Depression in Nondemented Patients with Essential Tremor

    M. Petrova, O. Grigorova, M. Raycheva, L. Traykov (Sofia, Bulgaria)

  • Influence of controlled-release levodopa on quality of sleep and nocturnal movements

    E. Schaeffer, L. Zaunbrecher, I. Liepelt-Scarfone, C. Hansen, W. Maetzler, S. Nussbaum, B. Roeben, M. Elshehabi, P. Saraykin, S. Otterbein, J. Busch, D. Berg (Kiel, Germany)

  • Influence of demographic characteristics in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II.

    A. Santos, J. Ferreira, A. Lees, H. Reichmann, W. Poewe, F. Ikedo, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

  • Influence of disease duration in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II

    H. Gama, J. Ferreira, A. Lees, A. Antonini, O. Rascol, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

  • Influence of disease severity in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II

    H. Gama, A. Lees, J. Ferreira, O. Rascol, A. Antonini, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

  • Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson’s disease patients: post-hoc analysis from combined BIPARK-I and II.

    A. Santos, A. Lees, J. Ferreira, O. Rascol, A. Antonini, F. Ikedo, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

  • Influence of peripheral immune system on cognitive profile in Parkinson’s disease

    L. Magistrelli, E. Storelli, V. Milner, E. Rasini, F. Marino, M. Cosentino, C. Comi (Varese, Italy)

  • Influence of spatial filtering on EEG signal stochasticity measurements in Parkinson’s Disease

    D. Herraez-Aguilar, A. Maitín, R.. Perezzan, D. Del Castillo, I. Serrano, E. Rodríguez, E. Rocon, A. Arroyo, J. Andreo, J. Romero (Pozuelo de Alarcon, Spain)

  • Influence of the spinal manipulation on muscle spasticity: a randomized controlled trial

    L. Shestopalova, T. Voloshyn (Truskavets, Ukraine)

  • Inhibition of mitochondrial complexes induces unique transcriptomic and epigenetic profiles: implications to neurodegeneration induced movement disorders

    R. Sathyanarayanan, S. Bharath (Bangalore, India)

  • Inhibitory Repetitive Transcranial Magnetic Stimulation of Pre-Supplementary Motor Area Improves Levodopa-Induced Dyskinesia in Parkinson’s Disease

    A. Lohse, D. Meder, D. Herz, A. Løkkegaard, H. Siebner (Copenhagen, Denmark)

  • Initial programming in STN-DBS for Parkinson’s disease: Standard vs. Steered Stimulation

    R. Maciel, D. Soh, R. Munhoz, Y. Poon, S. Kalia, M. Hodaie, A. Lozano, A. Fasano (Toronto, ON, Canada)

  • Initial Validation of the Cortical Basal ganglia Functional Scale (CBFS) in two international, multicenter cohorts: 4RTNI and PROSPECT

    A. Boxer, P. Wang, H. Morris, G. Stebbins, A. Lang (Toronto, ON, Canada)

  • Inpatient vs outpatient workup of patients with ataxia and suspected paraneoplastic cerebellar degeneration: Does work-up location matter?

    N. Witek, M. Afshari, Y. Liu, B. Ouyang, D. Hall (Chicago, IL, USA)

  • Insight into the heterogeneity of essential tremor

    G. Paparella, M. Bologna, I. Berardelli, G. Ferrazzano, L. Angelini, P. Giustini, D. Alunni-Fegatelli, A. Berardelli (Rome, Italy)

  • Insomnia as clinical onset symptom in Juvenile Huntington’s Disease: Evaluation of a Family

    M. Gultekin (Kayseri, Turkey)

  • Inspiring Neurology Residents to Select Movement Disorders Fellowship Training

    K. Harper, T. Davis, F. Phibbs, PD. Charles (Nashville, TN, USA)

  • Instrumental evaluation of sleep disturbance and autonomic nervous system dysfunction in idiopathic Parkinson’s disease

    MD. Doręgowska, MT. Toś, JM. Malkiewicz, JS. Siuda, MR. Rudzińska-Bar (Katowice, Poland)

  • Intact visuomotor forward models in adults with Tourette Syndrome

    A. Djodari-Irani, L. Kurvits, T. Mainka, A. Kühn, C. Ganos, F. Ostendorf (Berlin, Germany)

  • Integrated therapy for Functional Movement Disorders: results from a pilot clinic

    S. Lidstone, L. Macgillivray, C. Marras, M. Josef, L. Muc, A. Lang (Toronto, ON, Canada)

  • Integrity of Mirror Neuron System in cervical dystonia: an fMRI study

    A. Castagna, S. Di Tella, V. Blasi, M. Cabinio, F. Baglio (Milano, Italy)

  • Intensity-based exercise groupings in Parkinson’s Disease: Analysis from the Parkinson’s Foundation Quality Improvement Initiative (PF-QII)

    D. Larson, A. Margolius, G. Hanzhi, S. Wu, A. Angela, M. Miriam, T. Simuni (Gainseville, FL, USA)

  • Interactions within Fine Motor Control Network in Task-specific Dystonia

    S. Merchant, E. Frangos, S. Horovitz, T. Popa, J. Parker, M. Hallett (Charleston, SC, USA)

  • Interactive dual task exercises delivered via smart speaker: a feasibility study

    J. Dean, J. Domingos (Aurora, CO, USA)

  • Interleaved deep brain stimulation for dyskinesia management in Parkinson’s disease

    C. Aquino, G. Duffley, D. Hedges, J. Vorwerk, P. House, H. Ferraz, J. Rolston, C. Butson, L. Schrock (Minneapolis, MN, USA)

  • Interleaving stimulation in Parkinson’s disease: interesting to whom?

    C. França, E. Barbosa, R. Iglesio, M. Teixeira, R. Cury (São Paulo, Brazil)

  • Interleaving stimulation mode can improve better the health-related quality of life in primary generalized or segmental dystonia than standard bilateral pallidal deep brain stimulation

    N. Kovács, A. Juhasz, D. Pintér, M. Harmat, I. Balás, J. Janszky (Pécs, Hungary)

  • Intermediate CAG repeat length in the HTT gene and comorbidity – The SHAPE Study (Swedish-Huntingtin-Alleles-and-PhenotypE)

    M. Ghazarian, E. Stattin, J. Sundblom, V. Niemelä (Uppsala, Sweden)

  • Internal pallidum stimulation reduces mobile generalized dystonia in Wilson’s disease

    S. Paschen, A. Helmers, J. Volkmann, G. Deuschl, D. Berg, KE. Zeuner (Kiel, Germany)

  • Intestinal Levodopa/Carbidopa Infusion as a Therapeutic Option for Freezing of Gait After Deep Brain Stimulation in Parkinson’s Disease

    B. González, S. Jauma, R. Gomez, C. Marzal, M. Calopa (Hospitalet de Llobregat, Spain)

  • Intestinal nerve damage and gut dysfunction in mouse models of Parkinson’s Disease

    R. Mcquade, R. Constable, E. Lei, M. Di Natale, J. Berger, J. Kauhausen, C. Parish, D. Finkelstein, J. Furness, S. Diwakarla (Melbourne, Australia)

  • Intraoperative test stimulation of the subthalamic nucleus reduces the search space for chronic stimulation settings in Parkinson’s disease

    V. Geraedts, R. van Ham, J. Marinus, J. van Hilten, A. Mosch, C. Hoffmann, N. Vd Gaag, MF. Contarino (Leiden, Netherlands)

  • INTREPID: A 2-Year Follow-Up of a Prospective, Double Blinded, Multi-Center Randomized Controlled Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant-Current Rechargeable System for Treatment of Parkinson’s Disease

    J. Vitek, R. Jain, L. Chen, I. Study Group, P. Starr (Minneapolis, MN, USA)

  • Introduction of an Assessment Toolkit Increases the Rate of DLB Diagnosis

    A. Surendranathan, J. Kane, A. Bentley, S. Barker, J. Taylor, A. Thomas, I. Mckeith, D. Burn, J. O'Brien (Cambridge, United Kingdom)

  • Intronic pentanucleotide TTTCA repeat insertions do not cause familial and sporadic cortical myoclonic tremor with epilepsy in the UK

    WY. Yau, H. Houlden (London, United Kingdom)

  • Investigating Physical and Cognitive Changes over Two Years in Patients with Moderate to Late Stage Parkinson’s Disease in Northumbria

    L. Macdonald, I. Sayers, S. Dempsey, W. Gray, A. Hand, R. Walker (North Shields, United Kingdom)

  • Investigating the cellular role of LRRK2 in the immune system

    I. Nazish, R. Bandopadhyay (London, United Kingdom)

  • Investigating the impact of a-synuclein pathology on human embryonic stem cell derived dopaminergic neurons transplanted in an accelerated a-synuclein rat model of Parkinson’s disease

    D. Hoban, S. Shrigley, L. Breger, J. Nelander Wahlestedt, T. Cardoso, B. Mattsson, K. Luk, M. Parmar, A. Björklund (Lund, Sweden)

  • Investigation into the causes of reduced caffeine levels in Parkinson’s disease

    MI. de Bartolo, G. Leodori, A. Fabbrini, M. Costanzo, D. Belvisi, A. Conte, S. Manetto, A. Ciogli, C. Villani, A. Berardelli, G. Fabbrini (Rome, Italy)

  • Investigation of 531 cases of neuromelanin sensitive imaging, about its characteristics by disease

    K. Matsuura, Y. Ii, M. Maeda, K. Tabei, M. Umino, H. Tomimoto (Tsu, Japan)

  • Investigation of back pain in patients with Parkinson’s Disease

    O. Yaremchuk, I. Yaremchuk (Chernivtsi, Ukraine)

  • Investigation of the Effects of Propranolol on DRD3, SLC1A2 and HTRA2 Gene Expression in Patients with Essential Tremor

    M. Gultekin, N. Kandemir, M. Mirza, M. Kara, N. Tascıoglu, M. Dundar (Kayseri, Turkey)

  • Investigation of the protective efficacy of alpha-synuclein-specific antibodies in a novel neuronal cell model for synucleinopathies

    A. Peukert, M. Höllerhage, W. Zago, G. Höglinger (Munich, Germany)

  • Involuntary movements with abnormal brain imaging: A Case Report

    W. Webb, P. Chapman, V. Sung, M. Dean (Birmingham, AL, USA)

  • Ipsilateral worsening of essential tremor by thalamic deep brain stimulation

    U. Hidding, C. Choe, B. Müller, C. Buhmann, W. Hamel, C. Moll, C. Gerloff, M. Pötter-Nerger, S. Zittel (Hamburg, Germany)

  • Ipsilesional arm levitation after left hemispheric stroke: a case series

    M. Klarendic, N. Prezelj, R. Berlot, V. Zgonc, M. Kojovic (Ljubljana, Slovenia)

  • Iron Supplementation for the Treatment of Restless Legs Syndrome – A Systematic Review and Meta-Analysis

    M. Kestenbaum, N. Lev (Kfar Saba, Israel)

  • Is 18F-FDG-PET/CT a helpful tool to diagnose PSP clinical variants?

    G. Marti-Andres, M. Riverol-Fernandez, R. Valentí-Azcárate, M. Fernández-Matarrubia, E. Prieto-Azcárate, J. Arbizu-Azcarate, MR. Luquin-Piudo (Pamplona, Spain)

  • Is awake physiological confirmation necessary for DBS treatment of Parkinson’s disease today? A comparison of intraoperative imaging, physiology, and physiology imaging-guided DBS in the past decade

    GH. Lu, ZX. Yin, YY. Luo, YW. Jin (Nanchang, China)

  • Is DAT imaging abnormality in Normal Pressure Hydrocephalus always suggestive of degeneration? Evidences from three cases

    C. Del Gamba, A. Bruno, D. Frosini, D. Volterrani, N. Benedetto, C. Pacchetti, P. Perrini, M. Cosottini, U. Bonuccelli, R. Ceravolo (Pisa, Italy)

  • Is directional stimulation of the VIM superior to omnidirectional stimulation in patients with essential tremor?

    S. Fliegen, P. Nikolov, C. Hartmann, P. Slotty, J. Vesper, A. Schnitzler, S. Groiß (Düsseldorf, Germany)

  • Is Dizziness a sign before DLB onset?

    M. Matsumura (Tokyo, Japan)

  • Is Microelectrode Recording mandatory for Deep Brain Stimulation in Parkinson’s disease?

    J. Bajaj, M. Singh, V. Goyal, S. Girishan, K. Garg (Delhi, India)

  • Is primary writing tremor a form fruste of dystonia?

    A. Latorre, L. Rocchi, A. Berardelli, J. Rothwell, K. Bhatia (Rome, Italy)

  • Is reduction in UPDRS-3 OFF score the best indicator of response to DBS?

    P. Millar Vernetti, M. Rossi, C. Terroba Chambi, M. Merello (Buenos Aires, Argentina)

  • Is Restless Legs Syndrome Usual in Patients with Sickle Cell Disease and Beta Thalassemia?

    E. Okuyucu, M. Guntel, E. Ucar, G. Oktay (Hatay, Turkey)

  • Is safinamide helpful in multiple system atrophy?

    R. Simões, A. Gonçalves, JJ. Ferreira (Lisboa, Portugal)

  • Is sprint running exercise feasible, safe and enjoyable to subjects with mild-to-moderate Parkinson’s disease?

    E. Monteiro, L. Peyré-Tartaruga, E. da Silva, A. Zanardi, P. Jimenez-Reyes, J. Morin, A. Pagnussat (Porto Alegre, Brazil)

  • Is teleneurology effective in screening for spasticity?

    K. Harper, B. Eoff, F. Phibbs, D. Isaacs, S. Gallion, E. Thomas, J. Scott, M. Hacker, D. Charles (Nashville, TN, USA)

  • Is the activation ratio of transversus abdominis associated with mobility and core endurance in patients with Idiopathic Parkinson’s Disease?: A Preliminary study

    B. Aktar, S. Ozyurek, E. Goz, B. Donmez Colakoglu, B. Balci (Izmir, Turkey)

  • Is the gene expression of TAF1 modified by the X-linked dystonia-parkinsonism-associated hexanucleotide repeat?

    K. Grütz, S. Schaake, B. Laabs, CJ. Reyes, U. Walter, D. Dressler, RD. Jamora, RL. Rosales, N. Brüggemann, K. Lohmann, IR. König, C. Klein, A. Westenberger (Lübeck, Germany)

  • Is the personal Kinetigraph useful in the management of Parkinson´s disease patients? A retrospective study from a tertiary movement disorder center

    E. Krause, J. Randhawa, R. Mehanna (Houston, TX, USA)

  • Is there evidence of bradykinesia in patients with Essential Tremor?

    D. Colella, M. Bologna, G. Paparella, A. Cannavacciuolo, S. Pietracupa, A. Guerra, A. Berardelli (Rome, Italy)

  • Is VIM-DBS in ET-plus patients as effective as in ET patients?

    J. Steffen, J. Petry-Schmelzer, T. Dembek, J. Becker, G. Fink, V. Visser-Vandewalle, M. Barbe (Cologne, Germany)

  • Isolated delusion in idiopathic Parkinson’s disease: particularities in a subgroup of patients

    A. Gonçalves, A. Delgado, J. Velosa, R. Simões, J. Vale (Loures, Portugal)

  • Isolated unilateral tensor veli palatini myoclonus causing objective tinnitus without palatal elevation

    C. Selvadurai, S. Schaefer (New Haven, CT, USA)

  • Ixcellence Network®, an International Innovative Educational Programme To Improve Cervical Dystonia And Spastic Paresis Management: Feedback survey from 839 attendees

    C. Colosimo, TM. Chung, LJ. Jacinto, K. Bhatia, A. Fulford-Smith, R. Bhidayasiri (Roma, Italy)

Jump to:  View All • a b c d e f g h [i] j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Safety and Tolerability of a Ketone Supplement in Parkinson's Disease
  • Successful external defibrillation in a patient with bilateral deep brain stimulation
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley